Xalkori to be funded in UK against rare lung cancer

31 May 2018

There is more good news for Pfizer (NYSE: PFE), after the UK’s National Institute for Health and Care Excellence (NICE) agreed to reimburse Xalkori (crizotinib).

The firm revealed on Wednesday that the US regulator had granted two Breakthrough Therapy designations for Xalkori (crizotinib), speeding up the regulatory process for two new indications in anaplastic large cell lymphoma and non-small cell lung cancer.

The announcement from the UK’s health technology assessor relates to patients with ROS1-positive advanced non-small cell lung cancer, who will be able to receive treatment with Xalkori via the Cancer Drugs Fund (CDF).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK